Abstract. Osteosarcoma is the most common primary bone tumor and predominantly affects children and adolescents. The prognosis for patients with osteosarcoma is poor. Therefore, the development of novel treatments for osteosarcoma is required. Photodynamic therapy (PDT) is a disease site-specific treatment that utilizes a photosensitizing agent along with light to kill cancer cells. This agent only works following activation by certain wavelengths of light. After the agent is absorbed by the cancer cells, light is then applied to the area to be treated. The light causes the drug to react with oxygen, which produces radical and reactive oxygen species that kill the cells. However, the immune reaction that occurs following PDT remains unknown. The present study demonstrated that the necrosis of osteosarcoma cells inhibited the function of dendritic cells. However, treatment of osteosarcoma cells with PDT restored the function of dendritic cells by upregulating heat shock protein 70. Taken together, the results of the present study provided insight into the subsequent molecular reaction following PDT treatment of osteosarcoma at the molecular level.
Introduction
Osteosarcoma is the most common primary bone tumor and predominantly affects children and adolescents (1) (2) (3) . The current treatment of osteosarcoma remains difficult, and osteosarcoma causes numerous mortalities due to its complex pathogenesis and resistance to conventional treatments (4) .
Photodynamic therapy (PDT) is a disease site-specific treatment. It involves the local systemic administration of a photosensitizer followed by irradiation of the targeted lesion site with non-thermal visible light of an appropriate wavelength. In the presence of molecular oxygen, the light irradiation of the photosensitizer and energy transfer may lead to a number of photochemical reactions and generation of various cytotoxic species, thereby inducing apoptosis and necrosis of the targeted lesion (5) . Osteosarcoma has been studied by our group for a number of years and have investigated the possibility of applying PDT to the treatment of osteosarcoma (6, 7) .
Previously, another study indicated that PDT causes acute inflammation, expression of heat-shock proteins, invasion and the infiltration of the tumor by leukocytes, and that it may increase the presentation of tumor-derived antigens to T cells by regulating dendritic cells (DCs) (8) .
DCs are a heterogeneous population of antigen-presenting cells. Their main function is to process antigens and present them to T cells to promote immunity toward foreign antigens and tolerance toward self-antigens (9) (10) (11) (12) (13) (14) (15) . It has been demonstrated that the inflammation milieu induced by PDT promoted the antigen-presenting function of DCs (16) .
It has been previously reported that PDT treatment results in the induction of apoptotic and necrotic cell death, and that immature DCs co-cultured with PDT-treated tumor cells results in effective homing to regional and peripheral lymph nodes and stimulation of the cytotoxic activity of T and natural killer cells (17) . However, the exact mechanism by which the DCs are initiated remains unclear. In the study, we firstly hypothesized that the necrosis of osteosarcoma cells inhibited the function of DCs and treatment with PDT restored the function of DCs. The present study may provide insight into the mechanism underling the function of DCs following the treatment of osteosarcoma via PDT.
Materials and methods

Mice.
A total of 20 C57BL/6 mice (6-8 weeks old, 21±2.1 g, male) were obtained from the Animal Center of the Second Military Medical University (Shanghai, China). A total of 10 DO11.10 OVA 323-339 -specific mice (6-8 weeks old, 21±2.1 g, male) with C57BL/6 background were obtained from the Jackson Laboratory (C57BL/6 x DO11.10). A total of 10 F1 mice (21±2.1 g, male) were prepared by crossing C57BL/6 mice with DO11.10 mice. All mice were maintained under specific pathogen-free conditions and used at 6-8 weeks of age. Mice were provided with ad libitum access to food and water. Room conditions were controlled for humidity (40-70%) and temperature (22±3˚C) with a 12/12 h light/dark cycle. The use of the mice was approved by the Ethics Committee of Tongji University (Shanghai, China).
Photodynamic therapy. The photodynamic treatments were performed at the Department of Orthopedics of Shanghai Tenth People's Hospital (Shanghai, China). The entire process was performed as previously described (18 (19) (20) (21) (22) . In brief, the back legs above the hip joint of each mouse were incised, with the knee and ankle joints intact. Following this, both ends of the bone were incised with scissors as close to the joints as possible, then a syringe was filled with ice-cold RPMI complete medium (cat no. 21875091; Gibco; Thermo Fisher Scientific, Inc.) and the syringe needle was inserted into the bone in order to flush out the bone marrow into a centrifuge tube, which was on ice. Following depletion of red cells, the suspensions were cultured at a density of 2x10 6 cells/ml in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.) with 10% fetal calf serum. rmGM-CSF (10 ng/ml; cat no. PMC2015; Thermo Fisher Scientific, Inc.) and rmIL-4 (1 ng/ml; cat no. RMIL4; Thermo Fisher Scientific, Inc.) were added at the beginning of the cell culture. The non-adherent cells were gently washed at day 3 or day 4. On day 5, the proliferating DC clusters were collected and purified by anti-CD11c microbeads (cat no. 130092465; Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) as immature DCs. Immature DCs were stimulated with LPS (1 µg/ml; cat no. 00-4976-93; Thermo Fisher Scientific, Inc.) for 12 h, and these cells were collected as mature DCs. The purity of the DCs was >95%, confirmed anti-CD11c conjugated to fluorescein isothiocyanate (cata no. 11-0114-85; Thermo Fisher Scientific, Inc.) by cytometry analysis (BD LSR II; BD Biosciences, Franklin Lakes, NJ, USA) as previously described (23) . The bone marrow-derived DCs were co-cultured with the remnants of osteosarcoma LM8 cells. DCs co-cultured with RPMI complete medium (cat no. 21875091; Gibco; Thermo Fisher Scientific, Inc.) with 10% fetal bovine serum (cat. no. 10100139; FBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) were used as the control. The cells were placed at 37˚C in a humidified 5% CO 2 incubator for 24 h.
Phenotype analysis. For assessing the DC phenotypes, cells were incubated with blocking buffer (0.5% BSA and 0.05% Sodium Azide in 1 x PBS) at room temperature for 30 min. These cells (5x10 5 ) were subsequently stained independently with fluorescein-conjugated monoclonal antibodies against cluster of differentiation CD80 (catalog no. 11-0809-42; 1:500), CD86 (catalog no. 12-0869-42; 1:1,000), Ia (catalog no. 11-0432-42; 1:1,000) or CD40 (catalog no. 11-1548-42; 1:1,000) (all Thermo Fisher Scientific, Inc.) in staining buffer (1% FBS with 0.09% NaN3) at room temperature for 20 min. Following washed by PBS three times and centrifugation at 500 x g for 3 min at 4˚C, cells were subsequently analyzed by FACS (BD LSR II) for expression of CD80, CD86, Ia and CD40. For assessing the myeloid-derived suppressor cell phenotypes, cells (5x10 5 ) were double-stained with fluorescein-conjugated monoclonal antibodies against Gr-1 and CD11b, and then these cells were analyzed by FACS using a BD LSR II flow cytometer (LSR II, 1.1.0) with BD FACSDiva TM software version 6.0 (BD LSR II; BD Biosciences, Franklin Lakes, NJ, USA) for Gr-1 and CD11b expression.
T-cell proliferation analysis. Ability of DCs in stimulating T cell proliferation were tested by DC-T cell cocultured experiment. In detail, OVA 323-339 -specific T-cell receptor (TCR)-transgenic mice (6-8 weeks) were euthanized for isolation of the spleen. The single-cell suspensions of spleen were produced by gentle grinding and filtration, and then the red blood cells were removed via red blood cell Lysis Buffer (cat. 00-433-57; Thermo Fisher Scientific, Inc.). The CD4 + T cells were purified using microbeads (CD4 + antibody-coated; Miltenyi Biotec GmbH). The CD4 + T cells (1x10 5 ) were co-cultured with DCs (1x10 
RNA sequencing (RNA-SEQ) and reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
Total RNA were extracted from LM8 cells by TRIzol ® Reagent (catalog no. 15596018, Thermo Fisher Scientific, Inc.). RNA-SEQ was performed by Shanghai Shengong Engineering Technology Service, Ltd. (Shanghai, China). The expression levels of heat shock protein 70 (HSP70), activating transcription factor 3 (ATF3), B-cell lymphoma 2 (Bcl-2), tumor protein (P)53, P21, P16 and P27 levels were analyzed by RT-qPCR. RNA were reversed-transcrpted by SuperScript TM First-Strand Synthesis System for RT-PCR (catalog no. 11904018, Thermo Fisher Scientific, Inc). The thermocycling conditions were 42˚C for 50 min, 70˚C for 15 min. PCR primers were constructed by Shanghai Shengong Engineering Technology Service, Ltd. qPCR reactions were performed in 96-well optical reaction plates using the cDNA equivalent of 20 ng total RNA for each sample in a total volume of 20 µl containing 1X SYBR ® Green PCR master mix (24) (cat. no. A25741; Thermo Fisher Scientific) and forward and reverse primers were listed as following: HSP70, forward, 5'-GAT GCC AGC GTA CAG TCC-3', reverse, 5'-ACA GCA TTT GTC ACT GTC TTT-3'; ATF3, forward, 5'-TGC AAA AGG AAA CTG ACC AAG-3', and reverse, 5'-CTG GCC TGG ATG TTG AAG CAT-3'; p53, forward, 5'-CCC CTC CTG GCC CCT GTC ATC TTC-3', and reverse, 5'-GCA GCG CCT CAC AAC CTC CGT CAT-3'; p21, forward, 5'-GAG GCC GGG ATG AGT TGG GAG GAG-3', and reverse 5'-CAG CCG GCG TTT GGA GTG GTA GAA-3'; p16, forward, 5'-GAG CAG CAT GGA GCC TTC GG, and reverse, 5'-CAT GGT TAC TGC CTC TGG TG-3'; p27, forward, 5'-GGT TAG CGG AGC AAT GCG-3', and reverse, 5'-TCC ACA GAA CCG GCA TTT G-3'; GAPDH, forward, 5'-CGA CCA CTT TGT CAA GCT CA-3', and reverse, 5'-AGG GGT CTA CAT GGC AAC TG-3'. The thermocycling conditions were as follows: 95˚C for 3 min and 40 cycles of amplification comprising 95˚C for 12 sec, appropriate annealing temperature (60˚C) for 30 sec, and 72˚C for 30 sec (25-27).
Statistical analysis. A two-tailed unpaired Student's t-test was
used to analyze the difference between two groups. Analysis of variance, followed by the least significant difference test, was used to analyze the difference among three groups. SPSS for Windows, v.16.0 (SPSS Inc., Chicago, IL, USA), was used to perform all statistical analyses. Values are expressed as the mean ± standard deviation of three independent tests. P<0.05 was considered to indicate a statistically significant difference.
Results
The remnants of LM8 cells inhibit the function of DCs.
To begin with, the effects of the lysis remnants of osteosarcoma cells on the function of DCs were determined. The bone marrow-derived DCs were co-cultured with the remnants of osteosarcoma LM8 cells. DCs co-cultured with medium were used as control. After a 48-h co-culture, the DCs were isolated for phenotype and cytokine analysis, and their ability to stimulate the proliferation of T-cells was also investigated. It was revealed that the remnants of LM8 cells significantly inhibited the expression of major histocompatibility complex 2 (MHC-2), CD40, CD86, CD80 and C-C chemokine receptor type 7 (Fig. 1A) . The treatment of LM8 cells decreased IL-12 levels and increased IL-10 levels (Fig. 1B) . The mixed lymphocyte reaction analysis revealed that the treatment of LM8 cells decreased the ability of DCs to stimulate T-cell proliferation (Fig. 1C) .
PDT treatment reduces the inhibitory function of the LM8 remnants.
To investigate the role of PDT in the inflammation, we first treated LM8 cells with PDT and then collected the remnants of LM8 treated cells (PDT-LM8) for co-cultured with the bone marrow-derived DCs. We found that PDT-LM8 upregulated MHC-2 expression (Fig. 2A) . We then analyzed the co-expression molecules and found that PDT-LM8 treated by PDT up-regulated the CD80, CD86, Ia, CD11c, CD40, and CCR7 (Fig. 2B) . The mixed lymphocyte reaction analysis revealed that the PDT treatment may increase the ability of DCs in stimulating T cell proliferation (Fig. 2C) .
HSP70 is upregulated by PDT.
To identify the key molecular elements altered in osteosarcoma cells treated with PDT, the differential gene expression between LM8 cells treated with PDT and the control was determined by RNA-SEQ analysis. The data indicated that HSP70 was upregulated in the PDT-treated LM8 cells (Fig. 3A) . As HSP70 serves an important role in the activation of DCs (28) (29) (30) , the expression of HSP70 and related genes, including ATF3, BCL2, P53, P21, P16 and P27, was subsequently assessed by RT-qPCR. It was revealed that HSP70 was upregulated following PDT treatment (Fig. 3B) . Next, the HSP70 levels were inhibited in LM8 cells via siRNA and then the remnants of these transfected LM8 cells were cultured with DCs. It was observed that the increased downregulation of HSP70 cells at least partly reduced the effect of PDT treatment on the phenotype of DCs (CD86 expression). Therefore, it was concluded that the HSP70 expression induced by PDT may promote the function of DCs (Fig. 3C) .
Discussion
PDT is a novel approach for the treatment of osteosarcoma. However, the underlying mechanisms affecting subsequent immune reaction remains unclear. The present study provided insights into these molecular mechanisms and revealed that the remnants of osteosarcoma cells inhibited the functions of DCs and that treatment with PDT reduced this inhibitory function. Notably, the upregulation of HSP70 was involved in the underlying mechanism regarding this phenomenon.
It has been established that the function of DCs in tumors is inhibited. In a previous study, authors revealed that the tumor microenvironment was able to induce DCs to differentiate into regulatory DCs with a CD11c(low) CD11b(high) Ia(low) phenotype and a high expression of IL-10, nitric oxide, vascular endothelial growth factor and arginase I. These tumor-educated regulatory DCs suppress T cell response (31) . Notably, PDT treatment changed the gene expression of osteosarcoma cells and induced upregulation of HSP70. HSP70 has been demonstrated to activate the function of DCs (28) (29) (30) . As it has been established that tumor-educated DCs develop into DCs with immune suppressive functions. The present study revealed that PDT treatment promoted the normal function of DCs.
However, for CD11c(low) CD11b(high) Ia(low) regulatory DCs, tumor-derived transforming growth factor β (TGF-β) and prostaglandin E2 (PGE2) are responsible for the generation of regulatory DCs. The present study revealed that upregulation of HSP70 reversed the inhibitory function of the tumor on DCs. Therefore, we concluded that there were two possible reasons for this: i) PDT treatment may prevent the process of tumor-educated DCs via HSP70, or ii) PDT treatment may re-educate the tumor-educated DCs in a HSP70-dependent manner.
In the process of inducing DCs with immune suppressive functions, the soluble factors TGF-β and PGE2 served central roles. Following PDT treatment, HSP70, an insoluble factor, was able to reverse the function of DCs. Therefore, the results of the present study indicated that soluble factors and other molecules expressed by tumors may affect the function of DCs.
Furthermore, these data also indicated that that p53 was upregulated following treatment of LM8 cells with PDT (Fig. 2B) . However, it was previously demonstrated that the p53 gene was most often mutated/deleted in human osteosarcoma (32, 33) , and it is possible that the OS cell lines used in those studies lacked p53 expression. Due to the fact that the results of the present study cannot confirm that p53 was upregulated by PDT treatment, this will be investigated in future studies.
In conclusion, the results of the present study revealed that the remnants of osteosarcoma treated with PDT induced the activation of DCs, and that the molecular mechanism involved upregulation of HSP70 expression induced by PDT. Therefore, the present study may provide novel insight into the treatment of osteosarcoma via PDT and its effects on the function of DCs.
